- Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
- Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
- Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
- Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
- Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
- Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
- Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
- Belite Bio Announces $25 Million Registered Direct Offering
- Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
More ▼
Key statistics
On Friday, Belite Bio Inc (BLTE:NAQ) closed at 45.50, -9.27% below its 52-week high of 50.15, set on Jun 13, 2024.
52-week range
Open | 45.53 |
---|---|
High | 45.77 |
Low | 44.91 |
Bid | 45.01 |
Offer | 46.20 |
Previous close | 45.75 |
Average volume | 58.68k |
---|---|
Shares outstanding | 30.40m |
Free float | 30.10m |
P/E (TTM) | -- |
Market cap | 1.39bn USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼